triazolam has been researched along with Hepatic Insufficiency in 1 studies
Triazolam: A short-acting benzodiazepine used in the treatment of insomnia. Some countries temporarily withdrew triazolam from the market because of concerns about adverse reactions, mostly psychological, associated with higher dose ranges. Its use at lower doses with appropriate care and labeling has been reaffirmed by the FDA and most other countries.
Hepatic Insufficiency: Conditions in which the LIVER functions fall below the normal ranges. Severe hepatic insufficiency may cause LIVER FAILURE or DEATH. Treatment may include LIVER TRANSPLANTATION.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This paper addresses the pharmacokinetic properties of eszopiclone and the extent to which the longer half-life of eszopiclone compared to other commonly used hypnotics (immediate-release zolpidem, modified-release zolpidem, triazolam, zaleplon) may translate into either improved efficacy in enhancing sleep maintenance, or increased probability of residual sedative or performance-impairing effects." | 1.38 | Pharmacokinetic evaluation of eszopiclone: clinical and therapeutic implications. ( Greenblatt, DJ; Zammit, GK, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Greenblatt, DJ | 1 |
| Zammit, GK | 1 |
1 other study available for triazolam and Hepatic Insufficiency
| Article | Year |
|---|---|
Pharmacokinetic evaluation of eszopiclone: clinical and therapeutic implications.
Topics: Acetamides; Adult; Aged; Azabicyclo Compounds; Clinical Trials as Topic; Cytochrome P-450 CYP3A; Cyt | 2012 |